Home/ Stocks/ ACRS

Aclaris Therapeutics, Inc.

ACRS XNAS

$4.93 +0.09 (+1.85%) ▲ 15-min delayed

Open

$4.83

High

$4.94

Low

$4.66

Volume

1.21M

Market Cap

$688.54M

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 73 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$2.00M	$-19,824,000	$-0.15
FY 2025	$7.83M	$-64,923,000	$-0.53
Q3 2025	$3.30M	$-14,614,000	$-0.12
Q2 2025	$1.78M	$-15,429,000	$-0.13

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for ACRS yet. Check out our latest market news or earnings calendar.

Get ACRS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Aclaris Therapeutics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.